Drekab, Through the grapevine, I heard there we
Post# of 9122
Posted On: 12/09/2016 12:49:05 PM
Drekab,
Through the grapevine, I heard there were at the least two companies that responded for initial talks with NNLX --- Roche Diagnostics and Emergent BioSolutions. Then the crisis ended. In the below press release, NNLX did state they didn't have the necessary resources to develop the test independently. Level Four Research facilities (BSL-4), necessary for working with hemorrhagic fever viruses, don't come cheap.
As for ZIKA, there's no advantage to finding it in 6 hours versus 2 weeks --- it's not an immediate life threat.
This was a press release from 10/14/14:
"HUBBARD, Ohio--(BUSINESS WIRE)--NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that it is configuring its N-Assay Rapid diagnostic kits for both Ebola Virus and Enterovirus detection and identification. NanoLogix CEO Bret Barnhizer stated, “The Company has been aware of the virus detection capabilities of the technology since the N-Assay development. Viruses viewed as public health concerns prior to Ebola and Enterovirus were Influenza, the common cold, and HIV, none of which have an immediate or near-immediate threat of mortality. Until recently, NanoLogix has been focused solely on the use of their N-Assay kit for bacteria detection and identification. Now, with the recent outbreaks of both Ebola and Enterovirus there is an immediate need for configuration of the N-Assay for viruses. NanoLogix facilities are not designed for work on viruses, for this specific project we are seeking a corporate partner with the facilities necessary to bring the new N-Assay (V) to the market as quickly as possible. We consider this a matter of national security and an emergency priority. We are in discussions with potential partners, positioned with strong ties to the US government, who understand the serious threat these viruses represent.”
Scott
Through the grapevine, I heard there were at the least two companies that responded for initial talks with NNLX --- Roche Diagnostics and Emergent BioSolutions. Then the crisis ended. In the below press release, NNLX did state they didn't have the necessary resources to develop the test independently. Level Four Research facilities (BSL-4), necessary for working with hemorrhagic fever viruses, don't come cheap.
As for ZIKA, there's no advantage to finding it in 6 hours versus 2 weeks --- it's not an immediate life threat.
This was a press release from 10/14/14:
"HUBBARD, Ohio--(BUSINESS WIRE)--NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that it is configuring its N-Assay Rapid diagnostic kits for both Ebola Virus and Enterovirus detection and identification. NanoLogix CEO Bret Barnhizer stated, “The Company has been aware of the virus detection capabilities of the technology since the N-Assay development. Viruses viewed as public health concerns prior to Ebola and Enterovirus were Influenza, the common cold, and HIV, none of which have an immediate or near-immediate threat of mortality. Until recently, NanoLogix has been focused solely on the use of their N-Assay kit for bacteria detection and identification. Now, with the recent outbreaks of both Ebola and Enterovirus there is an immediate need for configuration of the N-Assay for viruses. NanoLogix facilities are not designed for work on viruses, for this specific project we are seeking a corporate partner with the facilities necessary to bring the new N-Assay (V) to the market as quickly as possible. We consider this a matter of national security and an emergency priority. We are in discussions with potential partners, positioned with strong ties to the US government, who understand the serious threat these viruses represent.”
Scott
(4)
(0)Nanologix Inc (NNLX) Stock Research Links
Scroll down for more posts ▼